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Non-Hodgkin Lymphoma is one of the malignant diseases that has the most rapidly 
increasing incidence in many countries. IL10 is a potent cytokine, which has been considered to 
be involved in pathogenesis of non-Hodgkin lymphoma. Furthermore allelic variations in the 
genes that has been implicated in inflammation, such as interleukin 10 are candidate risk factors 
for NHL. This study was been conducted as a case-control experiment on 320 patients with 
NHL,
 
285 clinically normal subjects for IL10-1082 G/A SNP and 312 patients with NHL, 284 
clinically normal subjects for IL10-819 C/T SNP. After DNA extraction, Polymerase Chain 
Reaction (PCR) was carried out to amplify two promoter Single Nucleotide Polymorphisms 
(SNPs), IL10-1082 G/A (rs1800870) and IL10-819 C/T (rs1800871) of the IL10 gene. PCR 
products were subjected to BseRІ and MslІ for genotyping of the IL10-1082 G/A and IL10-819 
C/T respectively by analyzing the Restriction fragment length polymorphism (RFLP) patterns. 
Hardy-Weinberg equilibrium (HWE) of the genotype distribution in control population was 
examined with chi-square test. Association of the two SNPs with NHL in each of the three main 
ethnic groups (Malays, Chinese, and Indian) in Malaysia was examined using Fisher‟s exact test 
under allelic, dominant inheritance and recessive models. Genotype and allele frequencies of 
IL10-1082 G/A and IL10-819 C/T in all controls were in HWE. The results have indicated that 
IL10-1082 G/A polymorphism was not associated with NHL incidence. Conversely IL10-819 
C/T was associated with risk of NHL only in the Malay population under the allelic and 
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dominant inheritance model (P=0.0235, P=0.0297 respectively). However, further studies with 
extended sample size are required in order to confirm the association between IL10-819 C/T and 









































Non-Hodgkin Lymphoma adalah salah satu penyakit malignan yang mempunyai 
insiden yang paling pesat meningkat di banyak negara. IL10 adalah cytokine mujarab, 
yang telah dianggap sebagai terlibat dalam patogenesis limfoma non-Hodgkin. 
Tambahan pula allelic variasi dalam gen yang telah terbabit dalam keradangan, seperti 
interleukin 10 adalah faktor risiko calon untuk NHL. Kajian ini telah dijalankan sebagai 
uji kaji kes-kawalan ke atas 320 pesakit dengan NHL, 285 klinikal biasa subjek untuk 
IL10-1082 G / A SNP dan 312 pesakit dengan NHL, 284 mata pelajaran untuk IL10-819 
C / T Taggart klinikal biasa. Selepas pengekstrakan DNA Polymerase Chain Reaction 
(PCR) telah dijalankan untuk menguatkan dua polimorfisme penganjur Nukleotida 
Tunggal (SNPs), IL10-1082 G / A (rs1800870) dan IL10-819 C / T (rs1800871) gen 
IL10. Produk PCR tertakluk kepada BseRІ dan MslІ untuk genotyping IL10-1082 G / A 
dan IL10-819 C / T masing-masing dengan menganalisis serpihan Sekatan panjang 
polymorphism (RFLP) corak. Keseimbangan Hardy-Weinberg (HWE) pengagihan 
genotip dalam kawalan penduduk telah diperiksa dengan ujian khi-kuasa. Persatuan 
SNPs dua dengan NHL dalam setiap satu daripada tiga kumpulan etnik utama (Melayu, 
Cina, dan India) di Malaysia telah diperiksa menggunakan ujian yang tepat Fisher di 
bawah pusaka allelic, dominan dan resesif model. Genotip dan frekuensi allele IL10-
1082 G / A dan IL10-819 C / T dalam semua kawalan di HWE. Keputusan telah 
menyatakan bahawa IL10-1082 G / A polymorphism tidak dikaitkan dengan insiden 
NHL. Sebaliknya IL10-819 C / T telah dikaitkan dengan risiko NHL hanya di kalangan 
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penduduk Melayu di bawah model pusaka allelic dan dominan (P = 0,0235, P = 0,0297 
masing-masing). Walau bagaimanapun, kajian lanjut dengan saiz sampel lanjutan 
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